Abstract:BackgroundMetformin is a commonly used drug for the treatment of diabetes. Accumulating evidence suggests that it exerts anti-tumor effects in many cancers, including multiple myeloma (MM); however, the underlying molecular mechanisms have not been clearly elucidated.MethodsThe anti-myeloma effects of metformin were evaluated using human MM cell lines (RPMI8226 and U266) in vitro and in vivo NOD-SCID murine xenograft MM model. Cell viability was assessed with CCK8 and cell proliferation was measured by EdU incorporation assay. Cell cycle distribution and apoptosis were examined by flow cytometry. Transmission electron microscopy was used to visualized autophagosomes. Activation of AMPK and inhibition of mTORC1/C2 pathways was assessed by Western blot analysis. RPMI8226 cells and U266 cell lines with AMPK knockdown were generated by transfection with small interfering RNA targeting the AMPK-α1 and α2 subunits using Lipofectamine 2000 reagent.ResultsMetformin effectively inhibited the proliferation of MM cell lines, an effect that was associated with the induction of autophagy and G0/G1 cell cycle arrest, but not apoptosis. Metformin activated AMPK and repressed both mTORC1 and mTORC2 signaling pathways in myeloma cells as well as downstream molecular signaling pathways, such as p-4EBP1 and p-AKT. AMPK activation resulted in direct phosphorylation and activation of tuberous sclerosis complex 2 (TSC2), leading to inhibition of the mammalian target of rapamycin (mTOR). In addition, metformin inhibited myeloma cell growth in an AMPK-dependent manner. The xenograft mouse model further confirmed that metformin inhibited tumor growth by upregulation of AMPK and downregulation of mTOR.ConclusionsMetformin inhibits the proliferation of myeloma cells by inducing autophagy and cell-cycle arrest. Our results suggest that the molecular mechanism involves dual repression of mTORC1 and mTORC2 pathways via AMPK activation. Our study provides a theoretical basis for the development of novel strategies for the treatment of MM using metformin as an already approved and safe drug.

Metformin Inhibits Cell Growth by Upregulating Microrna-26A in Renal Cancer Cells.

Metformin Alters the Expression Profiles of Micrornas in Human Pancreatic Cancer Cells

The Antidiabetic Drug Metformin Inhibits The Proliferation Of Bladder Cancer Cells In Vitro And In Vivo

Metformin and MiR-365 Synergistically Promote the Apoptosis of Gastric Cancer Cells Via MiR-365-PTEN-AMPK Axis.

Activation of AMPK by Metformin Promotes Renal Cancer Cell Proliferation under Glucose Deprivation Through Its Interaction with PKM2

Metformin inhibits growth of human non‑small cell lung cancer cells via liver kinase B‑1‑independent activation of adenosine monophosphate‑activated protein kinase

Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling.

PlGF Signaling and Macrophage Repolarization Contribute to the Anti-Neoplastic Effect of Metformin

Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production

Metformin is Associated with Reduced Cell Proliferation in Human Endometrial Cancer by Inbibiting PI3K/AKT/mTOR Signaling.

Metformin Regulates the Effect of miR-26a-5p Expression on Breast Cancer MCF7 Cells

Metformin blocks MYC protein synthesis in colorectal cancer via mTOR-4EBP-eIF4E and MNK-1-eIF4G-eIF4E signaling.

UCA1 involved in the metformin-regulated bladder cancer cell proliferation and glycolysis

Anti-metastatic effect of metformin via repression of interleukin 6-induced epithelial–mesenchymal transition in human colon cancer cells

A New Role for an Old Drug: Metformin Targets MicroRNAs in Treating Diabetes and Cancer

Mir-27A-mediated Antiproliferative Effects of Metformin on the Breast Cancer Cell Line MCF-7.

Metformin Inhibits Human Non-Small Cell Lung Cancer by Regulating AMPK–CEBPB–PDL1 Signaling Pathway

Metformin suppresses CRC growth by inducing apoptosis via ADORA1.

Metformin plays an antitumor role by downregulating inhibitory cells and immune checkpoint molecules while activating protective immune responses in breast cancer

Metformin Inhibited Pancreatic Cancer Growth by Upregulating Mir-143/145 Cluster and Suppressing MAPK Signaling Pathway

Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways